Ranbaxy Buys Biovel For An Entry Into Vaccines and Biotherapeutics
This article was originally published in The Pink Sheet Daily
Executive Summary
Ranbaxy clinched a deal with Bangalore-based Biovel in an asset buyout that is expected to help it gain foothold in a market that reached $700 million in India and $21 billion in worldwide sales in 2008.
You may also be interested in...
Daiichi Sankyo Acquires U.S. Generic Injectables Maker PharmaForce
TOKYO - Daiichi Sankyo's U.S. subsidiary, Luitpold Pharmaceutical of New York has fully acquired PharmaForce of Columbus, Ohio, a specialty injectable pharmaceutical company, the Tokyo-based company said
Indian Tribunal Back Zenotech, Daiichi Sankyo's Struggle On Open Offer Price Continues
MUMBAI - Daiichi Sankyo's year-long struggle to wrest control of India's biotech and oncology start-up Zenotech Labs received yet another setback as the Securities Appellate Tribunal backed the founder promoters of the Hyderabad-based company led by Jayaram Chigurupati and asked the Japanese company to increase the offer price for the shares to further bolster its shareholding
As Pfizer-Wyeth Combine Eye Vaccines Business, Novartis, GSK, Sanofi-Aventis And Indian Companies Brace For The Challenge
MUMBAI - These may be early days for Pfizer and Wyeth to analyze growth strategies of their vaccines business in emerging markets like India, but existing players like GlaxoSmithKline, Merck, Novartis and a host of home-grown companies like Panacea Biotec, Serum Institute and Shantha Biotech already seem well positioned to accelerate their growth in the quickly emerging vaccines market